Ahead of the upcoming American Society of Hematology annual meeting, a multicenter study published in the Journal of Clinical ...
Eagles fan Christian Johnico misses his old life. These days, Johnico is not able to get off the couch and into his car without assistance. He struggles to get out of bed due to aches and pains, and ...
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with ...
In this video, Catherine S. Diefenbach, MD, discusses highlights from the 2025 Lymphoma, Leukemia & Myeloma Congress.
Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...
Seattle Genetics (NASDAQ:SGEN) initiates a 110-subject, randomized, open-label, multi-center Phase 2 clinical trial assessing ADCETRIS (brentuximab vedotin), in combination with Roche's (OTCQX:RHHBY) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback